BIOMAT Database Logo BIOMAT Database Logo

Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. 1993

R I Nicholson, and R A McClelland, and P Finlay, and C L Eaton, and W J Gullick, and A R Dixon, and J F Robertson, and I O Ellis, and R W Blamey
Breast Cancer Unit, University of Wales College of Medicine, Heath Park, Cardiff, U.K.

The expression of the epidermal growth factor receptor (EGF-R), c-erbB-2 protein product and Ki67 have been evaluated in 105 breast cancers of known responsiveness to endocrine therapy using immunohistochemistry. EGF-R staining was observed in 62 of the tumours and was significantly associated with elevated rates of cell proliferation (%Ki67 positive cells) and loss of hormone sensitivity. In contrast, c-erbB-2 expression was not correlated with cell proliferation rates and was less strongly related to hormone insensitivity. Subdivision of the EGF-R data according to c-erbB-2 measurements revealed an association between c-erbB-2 immunostaining and worsened patient outlook and hormone insensitivity in moderately EGF-R-positive tumours. c-erbB-2 immunostaining in highly EGF-R-positive tumours did not further contribute to the already poor prognosis of these patients. These data confirm the prognostic importance of EGF-R measurements in breast cancer and may infer a functional interaction between this protein and the c-erbB-2 protein product in the aberrant growth of a subset of breast tumours.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008938 Mitosis A type of CELL NUCLEUS division by means of which the two daughter nuclei normally receive identical complements of the number of CHROMOSOMES of the somatic cells of the species. M Phase, Mitotic,Mitotic M Phase,M Phases, Mitotic,Mitoses,Mitotic M Phases,Phase, Mitotic M,Phases, Mitotic M
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009687 Nuclear Proteins Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus. Nucleolar Protein,Nucleolar Proteins,Nuclear Protein,Protein, Nuclear,Protein, Nucleolar,Proteins, Nuclear,Proteins, Nucleolar
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013629 Tamoxifen One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM. ICI-46,474,ICI-46474,ICI-47699,Nolvadex,Novaldex,Soltamox,Tamoxifen Citrate,Tomaxithen,Zitazonium,Citrate, Tamoxifen,ICI 46,474,ICI 46474,ICI 47699,ICI46,474,ICI46474,ICI47699

Related Publications

R I Nicholson, and R A McClelland, and P Finlay, and C L Eaton, and W J Gullick, and A R Dixon, and J F Robertson, and I O Ellis, and R W Blamey
Immunohistochemical expression of c-erbB-2 oncoprotein and EGF-R in pre- and postmenopausal breast cancer.
November 1998, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica,
R I Nicholson, and R A McClelland, and P Finlay, and C L Eaton, and W J Gullick, and A R Dixon, and J F Robertson, and I O Ellis, and R W Blamey
p34cdc2 in invasive breast cancer: relationship to DNA content, Ki67 index and c-erbB-2 expression.
December 1998, Histopathology,
R I Nicholson, and R A McClelland, and P Finlay, and C L Eaton, and W J Gullick, and A R Dixon, and J F Robertson, and I O Ellis, and R W Blamey
Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer.
December 1991, Oncogene,
R I Nicholson, and R A McClelland, and P Finlay, and C L Eaton, and W J Gullick, and A R Dixon, and J F Robertson, and I O Ellis, and R W Blamey
Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.
January 1992, British journal of cancer,
R I Nicholson, and R A McClelland, and P Finlay, and C L Eaton, and W J Gullick, and A R Dixon, and J F Robertson, and I O Ellis, and R W Blamey
C-erbB-2 immunostaining in laryngeal cancer.
January 1999, Acta oto-laryngologica,
R I Nicholson, and R A McClelland, and P Finlay, and C L Eaton, and W J Gullick, and A R Dixon, and J F Robertson, and I O Ellis, and R W Blamey
Retrospective c-erbB-2 immunostaining in aspiration cytology of breast cancer.
January 1994, Diagnostic cytopathology,
R I Nicholson, and R A McClelland, and P Finlay, and C L Eaton, and W J Gullick, and A R Dixon, and J F Robertson, and I O Ellis, and R W Blamey
c-erbB-2 protein expression in node negative breast cancer.
July 1990, Annals of oncology : official journal of the European Society for Medical Oncology,
R I Nicholson, and R A McClelland, and P Finlay, and C L Eaton, and W J Gullick, and A R Dixon, and J F Robertson, and I O Ellis, and R W Blamey
The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer.
March 1991, British journal of cancer,
R I Nicholson, and R A McClelland, and P Finlay, and C L Eaton, and W J Gullick, and A R Dixon, and J F Robertson, and I O Ellis, and R W Blamey
Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.
December 2000, Clinical cancer research : an official journal of the American Association for Cancer Research,
R I Nicholson, and R A McClelland, and P Finlay, and C L Eaton, and W J Gullick, and A R Dixon, and J F Robertson, and I O Ellis, and R W Blamey
c-erbB-2 expression in primary breast cancer.
January 1999, The International journal of biological markers,
Copied contents to your clipboard!